April 14th 2025
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Evaluating Impurities in Drugs (Part III of III)
April 2nd 2012In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.